Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
about
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerInhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer TherapyRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceEZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsAn intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.ABC transporters: unvalidated therapeutic targets in cancer and the CNSDrug therapy for hereditary cancersThe potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?PARP1 Inhibitors: antitumor drug design.FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.Preventive evolutionary medicine of cancersA three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.Therapeutic applications of PARP inhibitors: anticancer therapy and beyondTopotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.The clinical development of inhibitors of poly(ADP-ribose) polymerase.Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes.Mouse models of BRCA1 and their application to breast cancer research.Understanding resistance to combination chemotherapy.Opportunities and hurdles in the treatment of BRCA1-related breast cancer.The importance of drug transporters in human pluripotent stem cells and in early tissue differentiation.Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.Multidrug resistance in breast cancer: from in vitro models to clinical studies.The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
P2860
Q24632628-225EE295-2F72-4DAC-91A1-5FFB6BAC49CBQ26796576-ED6896AC-D0EF-4750-A026-4292E1B110C5Q26865927-4D4F8163-BBDF-4963-84E3-0555560B7181Q27318449-D5A6EA1E-2E06-40A6-AA4A-99FE36112B35Q28485864-72C253F5-D0AE-474E-8201-7170AB200B40Q33395375-D7BE9772-779A-4C22-826E-9E6D7A14A37BQ34592125-20728B75-FF63-4E03-BD8C-99DED0D563CBQ34619763-72EA4751-08C3-4675-9CE7-F43050B7CE9AQ35056738-D04F760B-1E0B-494D-AA3E-4B78B98B0825Q35208929-C099C1D7-7337-4561-B6CC-6863088AFD92Q35534509-1E9E5FBD-0A02-4AA1-8A93-59226F59415CQ35902206-BC65969F-234F-44B3-97C0-B6CEFC0833FDQ36037500-F42BDF60-1E4E-4FCD-9F51-1CAB550E82E5Q36175159-7381CAD9-5CEF-494B-8C95-D638C1F79FC6Q36309467-061EDF7F-A319-4DDE-8134-8CA30362D0DBQ36406519-51388C6E-F3CB-479B-BF84-16739074B925Q36456104-BB5F1EBF-36C9-4DAA-9EDD-AD889C370635Q36595780-F52F3F0E-2950-4B1C-A2D0-954F804D640AQ36803539-20A51B79-DA68-4FFF-BA40-BD88E94C044DQ36853236-6DB4DE45-4ABA-446B-BD1A-E19E2BC95C55Q36916288-4E3970F3-EA56-4C5A-9E60-614362F3C0BAQ36933976-6F520766-429D-4CB6-B43F-643500E27767Q37018096-F3AD2D42-3DAC-47EB-8802-307127159043Q37665387-150F67BA-362E-4AF3-9B4C-FEF9F37982B9Q37834139-CEDF44BB-0660-4EDE-B193-4312CB4902AAQ37868449-EE62D62A-69EB-44D3-9392-627F455A140BQ38055069-CA940FFB-2155-4B31-AC5E-3E6CED17F55DQ38060916-CA7FBB26-5F04-4658-9113-3D7AEC280E73Q38129725-285263E8-6A98-43A4-ACB8-F4CEF6C848F2Q38642449-A4FF703E-115E-49D0-8D45-6FFE8D934985Q39372888-B0920D9D-0FAE-4D08-8C07-E56BE52710A6Q42065258-D6E312F8-EB99-40DF-87D1-9B1508273C34Q42695791-1C7DFDC0-2006-4A9F-AA96-125DE201087CQ47416545-AF4BD65B-406C-43EC-9B42-7641C187D0CBQ57790341-8128BDB0-14EF-4A68-9EA5-C621ECB0373A
P2860
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Sensitivity and acquired resis ...... omerase I inhibitor topotecan.
@en
Sensitivity and acquired resis ...... omerase I inhibitor topotecan.
@nl
type
label
Sensitivity and acquired resis ...... omerase I inhibitor topotecan.
@en
Sensitivity and acquired resis ...... omerase I inhibitor topotecan.
@nl
prefLabel
Sensitivity and acquired resis ...... omerase I inhibitor topotecan.
@en
Sensitivity and acquired resis ...... omerase I inhibitor topotecan.
@nl
P2093
P1433
P1476
Sensitivity and acquired resis ...... omerase I inhibitor topotecan.
@en
P2093
Anders O H Nygren
Ariena Kersbergen
Eline van der Burg
Janneke E Jaspers
Jos Jonkers
Niels de Water
Olaf van Tellingen
Piet Borst
Serge A L Zander
Sjöfn Gunnarsdottir
P304
P356
10.1158/0008-5472.CAN-09-3367
P407
P577
2010-02-09T00:00:00Z